{
  "id": "5e46c7e73f54159529000009",
  "type": "summary",
  "question": "What is herceptin?",
  "ideal_answer": "Herceptin is a second generation tyrosine kinase inhibitor, that serves as an effective and approved oral therapy for patients with HER2-positive breast cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/15695389",
    "http://www.ncbi.nlm.nih.gov/pubmed/23830593",
    "http://www.ncbi.nlm.nih.gov/pubmed/29405790",
    "http://www.ncbi.nlm.nih.gov/pubmed/29305325",
    "http://www.ncbi.nlm.nih.gov/pubmed/15087020",
    "http://www.ncbi.nlm.nih.gov/pubmed/19398090",
    "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
    "http://www.ncbi.nlm.nih.gov/pubmed/29544445",
    "http://www.ncbi.nlm.nih.gov/pubmed/31822364",
    "http://www.ncbi.nlm.nih.gov/pubmed/14666732",
    "http://www.ncbi.nlm.nih.gov/pubmed/15868447",
    "http://www.ncbi.nlm.nih.gov/pubmed/12422054",
    "http://www.ncbi.nlm.nih.gov/pubmed/29671404",
    "http://www.ncbi.nlm.nih.gov/pubmed/19593441",
    "http://www.ncbi.nlm.nih.gov/pubmed/11768602",
    "http://www.ncbi.nlm.nih.gov/pubmed/25377592",
    "http://www.ncbi.nlm.nih.gov/pubmed/29434878",
    "http://www.ncbi.nlm.nih.gov/pubmed/21992561",
    "http://www.ncbi.nlm.nih.gov/pubmed/22934911",
    "http://www.ncbi.nlm.nih.gov/pubmed/19497323"
  ],
  "snippets": [
    {
      "text": "Trastuzumab (Herceptin\u00ae [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29544445",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Breast cancer (BCa) is the most common cancer affecting women worldwide. Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in ~20-25% of invasive ductal breast carcinomas and is associated with the more aggressive phenotype. Herceptin, a humanized antibody against HER2, is a standard therapy in HER2-overexpressing cases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29434878",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab (Herceptin\u00ae), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2+ breast cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29305325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "HER2-positive breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival. Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29405790",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Trastuzumab (Herceptin), a monoclonal antibody against a membrane-proximal epitope in the extracellular region of erbB2, shows a therapeutic effect against a fraction of erbB2-amplified breast tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15695389",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND & OBJECTIVE\n\nHerceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor (HER-2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15087020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical use of Herceptin (trastuzumab), which is a humanized monoclonal antibody against HER2, started for patients with HER2-overexpressing breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14666732",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12422054",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2 __sup__ + __end_sup__  breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a humanised mouse antibody that targets and inactivates HER-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21992561",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\n\nHerceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19593441",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a well-received antibody drug for HER2 positive gastric cancer . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31822364",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a recombinant humanized Her2 antibody used to treat breast cancer patients with Her2 overexpression . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a monoclonal antibody against HER2 , which is a member of the epidermal growth factor receptor ( ErbB ) family and is overexpressed in many cancers . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19497323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor ( HER-2) . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15087020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a major drug used to treat HER2 positive breast cancer . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29671404",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a humanized antibody that binds to the product of the HER-2 oncogene. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11768602",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nTrastuzumab (Herceptin(\u00ae)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25377592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a HER-2 targeted antibody that being widely used for the management of HER-2 positive breast cancer, which demonstrate significant benefits in both the metastatic and adjuvant settings.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23830593",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a humanised mouse antibody that targets and inactivates HER-2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21992561",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a recombinant humanized Her2 antibody used to treat breast cancer patients with Her2 overexpression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a monoclonal antibody against HER2, which is a member of the epidermal growth factor receptor (ErbB) family and is overexpressed in many cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19497323",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor (HER-2).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15087020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin/Trastuzumab is a humanized IgG1\u03ba light chain antibody used to treat some forms of breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22934911",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2+ breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29163501",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin (trastuzumab) is an adjuvant chemotherapy agent used in treatment of certain breast cancers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19398090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19593441",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}